Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2
(IDH2) occur in a variety of myeloid malignancies and solid tumors. Mutant IDH proteins …

HER2-positive breast cancer is a highly heterogeneous tumor, and about 30% of patients
still suffer from recurrence and metastasis after trastuzumab targeted therapy. Predicting …

Visual inspection of histopathology slides is one of the main methods used by pathologists
to assess the stage, type and subtype of lung tumors. Adenocarcinoma (LUAD) and …

The efficacy of chimeric antigen receptor (CAR) T cell therapy is hampered by relapse in
hematologic malignancies and by hyporesponsiveness in solid tumors. Long-lived memory …

Triple-negative breast cancer is viewed clinically as an aggressive subgroup of breast
cancer. In fact, most triple-negative breast cancers are poor-prognosis tumors with a …

Pre-symptomatic screening of genetic alterations might help identify subpopulations of
individuals that could enter into early access prevention programs. Since liquid biopsy is …

The most frequently mutated metabolic genes in human cancer are those encoding the
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been …

Adenomyoepithelioma of the breast is a rare tumor characterized by epithelial−
myoepithelial differentiation, whose genetic underpinning is largely unknown. Here we show …

Significance: Cancer cells are stabilized in an undifferentiated state similar to stem cells.
This leads to profound modifications of their metabolism, which further modifies their …